Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes
Open accessThe DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Dual-antiplatelet therapy with aspirin and a thienopyridine is a cornerstone of treatment to prevent thrombotic complications of acute coronary syndromes and percutaneous coronary intervention. METHODS: To compare prasugrel, a new thienopyridine, with clopidogrel, we randomly assigned 13,608 patients with moderate-to-high-risk acute coronary syndromes with scheduled percutaneous coronary intervention to receive prasugrel (a 60-mg loading dose and a 10-mg daily maintenance dose) or clopidogrel (a 300-mg loading dose and a 75-mg daily maintenance dose), for 6 to 15 months. The primary efficacy end point was death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke. The key safety end point was major bleeding. RESULTS: The primary efficacy end point occurred in 12.1% of patients receiving clopidogrel and 9.9% of patients receiving prasugrel (hazard ratio for prasugrel vs. clopidogrel, 0.81; 95% confidence interval [CI], 0.73 to 0.90; P<0.001). We also found significant reductions in the prasugrel group in the rates of myocardial infarction (9.7% for clopidogrel vs. 7.4% for prasugrel; P<0.001), urgent target-vessel revascularization (3.7% vs. 2.5%; P<0.001), and stent thrombosis (2.4% vs. 1.1%; P<0.001). Major bleeding was observed in 2.4% of patients receiving prasugrel and in 1.8% of patients receiving clopidogrel (hazard ratio, 1.32; 95% CI, 1.03 to 1.68; P=0.03). Also greater in the prasugrel group was the rate of life-threatening bleeding (1.4% vs. 0.9%; P=0.01), including nonfatal bleeding (1.1% vs. 0.9%; hazard ratio, 1.25; P=0.23) and fatal bleeding (0.4% vs. 0.1%; P=0.002). CONCLUSIONS: In patients with acute coronary syndromes with scheduled percutaneous coronary intervention, prasugrel therapy was associated with significantly reduced rates of ischemic events, including stent thrombosis, but with an increased risk of major bleeding, including fatal bleeding. Overall mortality did not differ significantly between treatment groups. (ClinicalTrials.gov number, NCT00097591 [ClinicalTrials.gov].)
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In patients with ACS undergoing PCI, 12 months' DAPT with low-dose ASA and prasugrel or ticagrelor was superior to DAPT with clopidogrel in the diabetes sub-group of the respective RCTs, with a benefit-risk profile similar to the overall trial populations (Supplementary data online, Tables S12-13).”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [310]
In the citing paper
“With prasugrel, the primary efficacy endpoint occurred in 9.9% of patients as compared with 12.1% receiving clopidogrel (HR 0.81, 95% CI 0.73-0.90;P , 0.001).The risk of major bleeding was increased with prasugrel.501”
From European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) (2012) · cites this paper as [501]
In the citing paper
“With ticagrelor given for 12 months the composite endpoint of death from vascular causes, myocardial infarction, or stroke occurred in 9.8% as compared with 11.7% of those receiving clopidogrel (HR 0.84, 95% CI 0.77-0.92;P , 0.001).No significant difference in rate of major bleeding was found.501 -503”
From European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) (2012) · cites this paper as [501]
In the citing paper
“In patients with ACS for whom an early invasive strategy is planned, dual antiplatelet therapy with a P2Y12 inhibitor (ticagrelor or prasugrel) added to aspirin was superior to clopidogrel and aspirin.”
From European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) (2012) · cites this paper as [501]
Citations
Cites
Collaboration, A. T. (2002) · BMJ · doi:10.1136/bmj.324.7329.71 · Cited by 6,943
(2001) · New England Journal of Medicine · doi:10.1056/nejmoa010746 · Cited by 6,470
Antman, E. M., Cohen, M., Bernink, P. J. L. M., McCabe, C. H., Horacek, T., Papuchis, G., Mautner, B., Corbalan, R., Radley, D., & Braunwald, E. (2000) · JAMA · doi:10.1001/jama.284.7.835 · Cited by 3,242
Self-citationSteinhubl, S. R., Berger, P. B., Mann III, J. T., Fry, E. T. A., DeLago, A., Wilmer, C., Topol, E. J., & for the CREDO Investigators (2002) · JAMA · doi:10.1001/jama.288.19.2411 · Cited by 3,078
Diener, H.-C., Bogousslavsky, J., Brass, L. M., Cimminiello, C., Csiba, L., Kaste, M., Leys, D., Matias-Guiu, J., & Rupprecht, H.-J. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16721-4 · Cited by 2,275
WRITING COMMITTEE MEMBERS, Smith, S. C., Feldman, T. E., Hirshfeld, J. W., Jacobs, A. K., Kern, M. J., King, S. B., Morrison, D. A., O’Neill, W. W., Schaff, H. V., et al. (2006) · Circulation · doi:10.1161/circulationaha.105.170815 · Cited by 2,218
Self-citationSabatine, M. S., Cannon, C. P., Gibson, C. M., López-Sendón, J. L., Montalescot, G., Theroux, P., Claeys, M. J., Cools, F., Hill, K. A., Skene, A. M., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050522 · Cited by 1,924
Self-citation(2005) · The Lancet · doi:10.1016/s0140-6736(05)67660-x · Cited by 1,858
Guidelines for Percutaneous Coronary Interventions
Silber, S., Albertsson, P., Avilés, F. F., Camici, P. G., Colombo, A., Hamm, C., Jørgensen, E., Marco, J., Nordrehaug, J.-E., Ruzyllo, W., et al. (2005) · European Heart Journal · doi:10.1093/eurheartj/ehi138 · Cited by 1,609
Stent Thrombosis in Randomized Clinical Trials of Drug-Eluting Stents
Mauri, L., Hsieh, W.-H., Massaro, J. M., Ho, K. K. L., D'Agostino, R., & Cutlip, D. E. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa067731 · Cited by 1,441
Research works printed but not linked: 1
- Varenhorst C, 2007, Eur Heart J, 28, 189
Cited by
Items 501–600 of 1,004
Capodanno, D., & Angiolillo, D. J. (2013) · Circulation · doi:10.1161/circulationaha.113.003675 · Cited by 114
Wiviott, S. D., White, H. D., Ohman, E. M., Fox, K. A. A., Armstrong, P. W., Prabhakaran, D., Hafley, G. E., Lokhnygina, Y. V., Boden, W. E., Hamm, C. W., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)61451-8 · Cited by 116
Self-citationAntithrombotic therapy for patients with STEMI undergoing primary PCI
Franchi, F., Rollini, F., & Angiolillo, D. J. (2017) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2017.18 · Cited by 115
Tarantini, G., Mojoli, M., Varbella, F., Caporale, R., Rigattieri, S., Andò, G., Cirillo, P. L., Pierini, S., Santarelli, A., Sganzerla, P., et al. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.08.053 · Cited by 121
Clopidogrel Pharmacogenomics and Risk of Inadequate Platelet Inhibition: US FDA Recommendations
Ellis, K., Stouffer, G. A., McLeod, H. L., & Lee, C. R. (2009) · Pharmacogenomics · doi:10.2217/pgs.09.143 · Cited by 116
Goto, S., Yamaguchi, T., Ikeda, Y., Kato, K., Yamaguchi, H., & Pk, J. (2010) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.3038 · Cited by 109
Schulz, S., Richardt, G., Laugwitz, K., Morath, T., Neudecker, J., Hoppmann, P., Mehran, R., Gershlick, A., Tölg, R., Fiedler, K. A., et al. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu182 · Cited by 108
Cohen, M. V., & Downey, J. M. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12903 · Cited by 120
“…have demon- strated that antiplatelet agents do indeed improve prognosis of patients after AMI and minimize complications of stenting (Antiplatelet Trialists’ Collaboration, 1994; Yusuf et al., 2001; Sabatine et al., 2005a,b; Wiviott et al., 2007; Wallentin et al., 2009; Bhatt et al., 2013).”
BackgroundMcCullough, P. A. (2007) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.03871106 · Cited by 144
Faxon, D. P., Eikelboom, J. W., Berger, P. B., Holmes, D. R., Bhatt, D. L., Moliterno, D. J., Becker, R. C., & Angiolillo, D. J. (2011) · Circulation: Cardiovascular Interventions · doi:10.1161/circinterventions.111.965186 · Cited by 108
Gross, P. L., & Weitz, J. I. (2009) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2009.98 · Cited by 124
“33 Prasugrel was found to be more effective than clopidogrel in preventing recurrent ischemic events after percutaneous coronary interventions (PCIs), but it caused more bleeding”
BackgroundImpact of Intraprocedural Stent Thrombosis During Percutaneous Coronary Intervention
Généreux, P., Stone, G. W., Harrington, R. A., Gibson, C. M., Steg, P. G., Brener, S. J., Angiolillo, D. J., Price, M. J., Prats, J., LaSalle, L., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.10.022 · Cited by 107
Self-citationManagement of cardiovascular disease in patients with kidney disease
Kahn, M. R., Robbins, M. J., Kim, M. C., & Fuster, V. (2013) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2013.15 · Cited by 115
Tanguay, J., Bell, A., Ackman, M. L., Bauer, R. D. C., Cartier, R., Chan, W., Douketis, J. D., Roussin, A., Schnell, G., Verma, S., et al. (2013) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2013.07.001 · Cited by 105
“The primary evidence supporting prasugrel in ACS remains the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis in Myocardial Infarction 38 (TRITON-TIMI 38).(9) As summarized in the initial CCS guidance,(1) prasugrel significantly reduced the relative risk…”
MethodAcquired Disorders of Platelet Function
Konkle, B. A. (2011) · Hematology · doi:10.1182/asheducation-2011.1.391 · Cited by 107
Vranckx, P., Valgimigli, M., Windecker, S., Steg, P. G., Hamm, C. W., Jüni, P., García‐García, H. M., van Es, G., & Serruys, P. W. J. C. (2016) · EuroIntervention · doi:10.4244/eijy15m11_07 · Cited by 109
Interventions for lower extremity peripheral artery disease
Hiramoto, J. S., Teraa, M., de Borst, G. J., & Conte, M. S. (2018) · Nature Reviews Cardiology · doi:10.1038/s41569-018-0005-0 · Cited by 114
2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: Executive Summary
Levine, G. N., Bates, E., Blankenship, J. C., Bailey, S. R., Bittl, J. A., Cercek, B., Chambers, C. E., Ellis, S. G., Guyton, R. A., Hollenberg, S. M., et al. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.08.006 · Cited by 118
Kikkert, W. J., van Geloven, N., van der Laan, M. H., Vis, M. M., Baan, J., Koch, K. T., Peters, R. J. G., de Winter, R. J., Piek, J. J., Tijssen, J. G. P., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.01.069 · Cited by 127
Dovlatova, N., Jakubowski, J. A., Sugidachi, A., & Heptinstall, S. (2008) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2008.03020.x · Cited by 106
Bonaca, M. P., Bhatt, D. L., Braunwald, E., Cohen, M. C., Steg, P. G., Storey, R. F., Held, P. H., Jensen, E. C., & Sabatine, M. S. (2014) · American Heart Journal · doi:10.1016/j.ahj.2013.12.020 · Cited by 109
Michelson, A. D. (2008) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.107.160689 · Cited by 106
Electronic health record design and implementation for pharmacogenomics: a local perspective
Peterson, J. F., Bowton, E., Field, J. R., Beller, M., Mitchell, J. M., Schildcrout, J. S., Gregg, W. M., Johnson, K. B., Jirjis, J. N., Roden, D. M., et al. (2013) · Genetics in Medicine · doi:10.1038/gim.2013.109 · Cited by 105
“…service architecture of the genotype-to-phe-notype translation layer allows simultaneous population of multiple clinical information systems, supporting the clinician through EHR views and patients through their access to a PHR hosted on a patient portal (see Supplementary Figure S2 online).”
Nijjer, S. S., Watson, G., Athanasiou, T., & Malik, I. S. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr151 · Cited by 107
Current concepts on coronary revascularization in diabetic patients
Roffi, M., Angiolillo, D. J., & Kappetein, A. P. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr305 · Cited by 105
“001) in patients (n 1⁄4 13 608) with moderate to high-risk ACS undergoing PCI over a period of 15 months.(55) A significant reduction in the stent throm-”
BackgroundPharmacological Treatment and Current Management of Peripheral Artery Disease
Bonaca, M. P., & Creager, M. A. (2015) · Circulation Research · doi:10.1161/circresaha.114.303505 · Cited by 112
Columbo, J. A., Lambour, A. J., Sundling, R. A., Chauhan, N. B., Bessen, S. Y., Linshaw, D. L., Kang, R., Riblet, N. B. V., Goodney, P. P., & Stone, D. H. (2017) · Annals of Surgery · doi:10.1097/sla.0000000000002279 · Cited by 109
Jeong, H. S., Hong, S. J., Cho, S.-A., Kim, J.-H., Cho, J. Y., Lee, S. H., Joo, H. J., Park, J. H., Yu, C. W., & Lim, D. (2017) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2017.05.064 · Cited by 105
“Unlike ticagrelor, administration of prasugrel did not improve cardiovascular mortality in TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with PrasugrelThrombolysis In Myocardial Infarction 38) (3).”
BackgroundWeighing Benefits and Risks — The FDA's Review of Prasugrel
Unger, E. F. (2009) · New England Journal of Medicine · doi:10.1056/nejmp0907122 · Cited by 105
Pharmacogenetics in Cardiovascular Antithrombotic Therapy
Marín, F. R., Gónzález‐Conejero, R., Capranzano, P., Bass, T. A., Roldán, V., & Angiolillo, D. J. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.04.084 · Cited by 110
Antiplatelet agents for chronic kidney disease
Palmer, S. C., Micco, L. D., Razavian, M., Craig, J. C., Perkovic, V., Pellegrini, F., Jardine, M., Webster, A. C., Zoungas, S., & Strippoli, G. F. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008834.pub3 · Cited by 116
White, H. D., Chew, D. P., Dauerman, H. L., Mahaffey, K. W., Gibson, C. M., Stone, G. W., Gruberg, L., Harrington, R. A., & Bhatt, D. L. (2012) · American Heart Journal · doi:10.1016/j.ahj.2011.11.001 · Cited by 107
Self-citationCost-Effectiveness of Genotype-Guided and Dual Antiplatelet Therapies in Acute Coronary Syndrome
Kazi, D. S., Garber, A. M., Shah, R. U., Dudley, R. A., Mell, M. W., Rhee, C., Moshkevich, S., Boothroyd, D. B., Owens, D. K., & Hlatky, M. A. (2014) · Annals of Internal Medicine · doi:10.7326/m13-1999 · Cited by 108
Nucleic acid scavengers inhibit thrombosis without increasing bleeding
Jain, S., Pitoc, G. A., Holl, E. K., Zhang, Y., Borst, L. B., Leong, K. W., Lee, J., & Sullenger, B. A. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1204928109 · Cited by 104
Cuisset, T., Loosveld, M., Morange, P., Quilici, J., Moro, P.-J., Saut, N., Gaborit, B., Castelli, C., Beguin, S., Grosdidier, C., et al. (2012) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2012.07.015 · Cited by 104
Gurbel, P. A., Fox, K. A. A., Tantry, U. S., Cate, H. T., & Weitz, J. I. (2019) · Circulation · doi:10.1161/circulationaha.118.033580 · Cited by 111
Mitsis, A., & Gragnano, F. (2020) · Current Cardiology Reviews · doi:10.2174/1573403x16999201210195702 · Cited by 138
Pride, Y. B., Tung, P., Mohanavelu, S., Zorkun, C. S., Wiviott, S. D., Antman, E. M., Giugliano, R. P., D, E. B. M., & Gibson, C. M. (2010) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2010.05.012 · Cited by 104
Self-citationBrown, D. G., Wilkerson, E. C., & Love, W. E. (2014) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2014.10.027 · Cited by 134
2013 ESC GUIDELINES ON THE MANAGEMENT OF STABLE CORONARY ARTERY DISEASE
Montalescot, G., Sechtem, U. P., Achenbach, S., Andreotti, F., Arden, C., Budaj, A., Bugiardini, R., Crea, F., Cuisset, T., Mario, C. D., et al. (2014) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2014-7-7-79 · Cited by 109
Self-citationEHA Guidelines on Management of Antithrombotic Treatments in Thrombocytopenic Patients With Cancer
Falanga, A., Leader, A., Ambaglio, C., Bagoly, Z., Castaman, G., Elalamy, I., Lecumberri, R., Niessner, A., Pabinger, I., Szmit, S., et al. (2022) · HemaSphere · doi:10.1097/hs9.0000000000000750 · Cited by 129
Sorich, M. J., Vitry, A. I., Ward, M., Horowitz, J. D., & McKinnon, R. A. (2010) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2010.03923.x · Cited by 103
Savonitto, S., Caracciolo, M., Cattaneo, M., & Servi, S. D. (2011) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2011.04456.x · Cited by 98
Neubauer, H. P., Kaiser, A. F., Endres, H. G., Krüger, J. C., Engelhardt, A., Lask, S., Pepinghege, F., Kusber, A., & Mügge, A. (2011) · BMC Medicine · doi:10.1186/1741-7015-9-3 · Cited by 112
P2Y12 Inhibition beyond Thrombosis: Effects on Inflammation
Mansour, A., Bachelot‐Loza, C., Nesseler, N., Gaussem, P., & Gouin‐Thibault, I. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21041391 · Cited by 113
P2Y12 receptor in platelet activation
Kim, S., & Kunapuli, S. P. (2011) · Platelets · doi:10.3109/09537104.2010.497231 · Cited by 101
“Prasugrel is associated with significant reduction in ischemic events including stent thrombosis but with a higher risk of major and fatal bleeding in patients with acute coronary syndromes undergoing percutaneous coronary intervention, as shown in the TRITON-TIMI 38 phase III trial [26].”
BackgroundThe evolution of antiplatelet therapy in cardiovascular disease
Yousuf, O. K., & Bhatt, D. L. (2011) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2011.96 · Cited by 114
“Two new potent ADP antagonists—prasugrel and ticagrelor—both show promise in reducing thrombotic complications”
BackgroundEfficacy and Safety of Vorapaxar in Patients With Prior Ischemic Stroke
Morrow, D. A., Alberts, M. J., Mohr, J. P., Ameriso, S. F., Bonaca, M. P., Goto, S., Hankey, G. J., Murphy, S. A., Scirica, B. M., & Braunwald, E. (2013) · Stroke · doi:10.1161/strokeaha.111.000433 · Cited by 102
Self-citationLewis, J. P., Backman, J., Reny, J., Bergmeijer, T. O., Mitchell, B. D., Ritchie, M. D., Déry, J., Pakyz, R. E., Gong, L., Ryan, K. A., et al. (2019) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvz045 · Cited by 100
Kushner, F. G., Hand, M. M., Smith, S. C., King, S. B., Anderson, J. L., Antman, E. M., Bailey, S. R., Bates, E., Blankenship, J. C., Casey, D. E., et al. (2009) · Catheterization and Cardiovascular Interventions · doi:10.1002/ccd.22351 · Cited by 113
“Randomized trials establishing its efficacy and providing data on bleeding risks used an LD of 300 mg orally followed by a daily oral dose of 75 mg.(26,27) Higher oral LDs such as 600 mg or more than 900 mg(36) of clopidogrel more rapidly inhibit platelet aggregation and achieve a higher absolute level of inhibition o…”
MethodSelf-citationJeong, Y., Hwang, J., Kim, I., Park, Y., Hwang, S., Lee, S., Kwak, C. H., & Park, S. (2010) · Circulation Cardiovascular Interventions · doi:10.1161/circinterventions.109.880179 · Cited by 99
Cao, D., Chandiramani, R., Chiarito, M., Claessen, B. E. P. M., & Mehran, R. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa824 · Cited by 104
Emerging roles of thioredoxin cycle enzymes in the central nervous system
Patenaude, A., Murthy, M. R. V., & Mirault, M.-É. (2005) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-005-4541-5 · Cited by 112
Kang, H.-S., Kwon, B. J., Kim, J. E., & Han, M. H. (2010) · American Journal of Neuroradiology · doi:10.3174/ajnr.a2051 · Cited by 99
“This was found to be associated with significant reduction in rates of ischemic events, but with increased risks of major bleeding and fatal bleeding in patients with acute coronary syndromes.(34) Temporary short-term administration of prasugrel during the periprocedural period might result in decreased procedure-rela…”
BackgroundManoukian, S. V. (2009) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2009.06.020 · Cited by 98
Patti, G., Caterina, R. D., Abbate, R., Andreotti, F., Biasucci, L. M., Calabrò, P., Cioni, G., Davì, G., Sciascio, G. D., Golia, E., et al. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu279 · Cited by 101
Gorog, D. A., Ferreiro, J. L., Ahrens, I., Ako, J., Geisler, T., Halvorsen, S., Huber, K., Jeong, Y., Navarese, E. P., Rubboli, A., et al. (2023) · Nature Reviews Cardiology · doi:10.1038/s41569-023-00901-2 · Cited by 111
2024 EACTS Guidelines on perioperative medication in adult cardiac surgery
Jeppsson, A., (Sweden), (.-C., Rocca, B., (Italy), (.-C., Hansson, E. C., (Sweden), Guðbjartsson, T., (Iceland), James, S. K., (Sweden), et al. (2024) · European Journal of Cardio-Thoracic Surgery · doi:10.1093/ejcts/ezae355 · Cited by 129
Silvain, J., Abtan, J., Kernéis, M., Martin, R., Finzi, J., Vignalou, J.-B., Barthélémy, O., O’Connor, S. A., Luyt, C. E., Bréchot, N., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.11.029 · Cited by 98
Self-citationFanning, J. P., Nyong, J., Scott, I. A., Aroney, C. N., & Walters, D. L. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004815.pub4 · Cited by 98
Jackson, L. R., Ju, C., Zettler, M., Messenger, J. C., Cohen, D. J., Stone, G. W., Baker, B. A., Effron, M., Peterson, E. D., & Wang, T. Y. (2015) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2015.08.018 · Cited by 97
“Nevertheless, novel and more potent antiplatelet agents, like prasugrel, are now in clinical use for patients with acute MI treated with PCI (8,9).”
BackgroundBellemain-Appaix, A., Kernéis, M., O’Connor, S. A., Silvain, J., Cucherat, M., Beygui, F., Barthélémy, O., Collet, J. ‐., Jacq, L., Bernasconi, F., et al. (2014) · BMJ · doi:10.1136/bmj.g6269 · Cited by 101
Self-citationAntiplatelet and Anticoagulation Therapy for Acute Coronary Syndromes
Bhatt, D. L., Hulot, J., Moliterno, D. J., & Harrington, R. A. (2014) · Circulation Research · doi:10.1161/circresaha.114.302737 · Cited by 102
“Prasugrel, also a thienopyridine but more potent than clopidogrel, was studied in patients with ACS undergoing PCI in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardial Infarction 38 (TRITON-TIMI 38).(36) A total of 13 608 patients were r…”
Franchi, F., Rollini, F., Aggarwal, N. R., Hu, J., Kureti, M., Durairaj, A., Duarte, V. E., Cho, J. R., Been, L. F., Zenni, M. M., et al. (2016) · Circulation · doi:10.1161/circulationaha.116.023402 · Cited by 101
Why does ticagrelor induce dyspnea?
Faioni, E. M., & Cattaneo, M. (2012) · Thrombosis and Haemostasis · doi:10.1160/th12-08-0547 · Cited by 98
Antiplatelet drug 'resistance'. Part 1: mechanisms and clinical measurements
Sweeny, J. M., Gorog, D. A., & Fuster, V. (2009) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2009.10 · Cited by 109
“Prospective, randomized, controlled, clinical trials designed to validate these observations are just starting to emerge in the literature, as are specific therapeutic options that can be used to overcome antiplatelet drug nonresponsiveness and improve patients' outcomes”
BackgroundAungraheeta, R., Conibear, A. E., Butler, M., Kelly, E., Nylander, S., Mumford, A. D., & Mundell, S. J. (2016) · Blood · doi:10.1182/blood-2016-03-707844 · Cited by 96
Moll, F. L., Baumgärtner, I., Jaff, M. R., Nwachuku, C., Tangelder, M. J. D., Ansel, G. M., Adams, G. L., Zeller, T., Rundback, J. H., GROSSO, M. A., et al. (2018) · Journal of Endovascular Therapy · doi:10.1177/1526602818760488 · Cited by 105
Antiplatelet therapy in cardiovascular disease: Current status and future directions
Passacquale, G., Sharma, P., Perera, D., & Ferro, A. (2022) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15221 · Cited by 117
“Other studies suggest that platelet function testing can result in improved outcomes, such as reduced stent thrombosis following PCI.84 Similarly, in cerebrovascular disease, the PRINCE trial (Table 2) showed that patients with minor stroke or TIA treated with ticagrelor plus aspirin exhibit reduced platelet reactivit…”
MethodInfluentialSehested, T. S. G., Carlson, N., Hansen, P. W., Gerds, T. A., Charlot, M. G., Torp-Pedersen, C. T., Køber, L., Gislason, G., Hlatky, M. A., & Fosbøl, E. L. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehz104 · Cited by 108
Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment (ISAR-REACT) 5 Trial Investigators, Schulz, S., Angiolillo, D. J., Antoniucci, D., Bernlochner, I., Hamm, C. W., Jaitner, J., Laugwitz, K., Mayer, K., von Merzljak, B., et al. (2013) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-013-9527-3 · Cited by 102
“Moreover, both drugs were shown to increase bleeding [9, 10].”
BackgroundMethodInfluentialSelf-citationKosoglou, T., Reyderman, L., Tiessen, R. G., van Vliet, A. A., Fales, R. R., Keller, R., Yang, B., & Cutler, D. L. (2011) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-011-1120-6 · Cited by 97
Effect of P2Y12 inhibitors on inflammation and immunity
Storey, R. F., & Thomas, M. (2015) · Thrombosis and Haemostasis · doi:10.1160/th14-12-1068 · Cited by 97
“Whilst this study only showed a non-significant trend towards lower levels of CRP, another study has shown that pre-treatment with clopidogrel prior to PCI was associated with lower levels of CRP (22).”
BackgroundInfluentialStatistical Controversies in Reporting of Clinical Trials
Pocock, S., McMurray, J. J. V., & Collier, T. J. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.10.023 · Cited by 101
Erlinge, D., Gurbel, P. A., James, S. K., Lindahl, T. L., Svensson, P. J., ten Berg, J. M., Foley, D. P., Wagner, H., Brown, P. B., Luo, J., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.05.023 · Cited by 96
“A prasugrel 5-mg MD should reduce bleeding risk, based on population pharmacokinetic (PK) substudy modeling in TRITON– TIMI 38 (2), which predicted active metabolite exposures with prasugrel 5 mg in VE patients, similar to the lowest exposure quartile in TRITON patients, blockers (”
BackgroundMethodResultInfluentialKaiser, C. A., Galatius, S., Jeger, R. V., Gilgen, N., Jensen, J. S., Naber, C. K., Alber, H. F., Wanitschek, M. M., Eberli, F. R., Kurz, D. J., et al. (2014) · Circulation · doi:10.1161/circulationaha.114.013520 · Cited by 100
Radial Access Reduces Mortality in Patients With Acute Coronary Syndromes
Andò, G., & Capodanno, D. (2016) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2015.12.008 · Cited by 100
“C ombined use of potent antithrombotic drugs and early invasive management in patients with ACS have prompted a substantial reduction in adverse ischemic events, at the cost of increased bleeding (1).”
BackgroundCryer, B., Bhatt, D. L., Lanza, F. L., Dong, J.-F., Lichtenberger, L. M., & Marathi, U. K. (2010) · The American Journal of Gastroenterology · doi:10.1038/ajg.2010.436 · Cited by 102
“Use of more potent antiplatelet agents, which have recently become clinically available, has been associated with increasing rates of GI bleeding (”
BackgroundMałek, Ł. A., Kisiel, B. M., Śpiewak, M., Grabowski, M., Filipiak, K. J., Kostrzewa, G., Huczek, Z., Płoski, R., & Opolski, G. (2008) · Circulation Journal · doi:10.1253/circj.72.1165 · Cited by 94
2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery: Executive Summary
Hillis, L. D., Smith, P. K., Anderson, J. L., Bittl, J. A., Bridges, C. R., Byrne, J. G., Cigarroa, J. E., DiSesa, V. J., Hiratzka, L. F., Hutter, A. M., et al. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.08.008 · Cited by 111
Gurbel, P. A., Bliden, K. P., Antonino, M. J., STEPHENS, G., Gretler, D. D., Jurek, M., Pakyz, R. E., Shuldiner, A. R., Conley, P. B., & Tantry, U. S. (2009) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2009.03648.x · Cited by 92
Byrne, R. A., Schulz, S., Mehilli, J., Iijima, R., Maßberg, S., Neumann, F., Berg, J. M. T., Schömig, A., & Kastrati, A. (2009) · American Heart Journal · doi:10.1016/j.ahj.2008.12.019 · Cited by 93
Self-citationVarenhorst, C., James, S. K., Erlinge, D., Braun, O. Ö., Brandt, J. T., Winters, K. J., Jakubowski, J. A., Olofsson, S., Wallentin, L. C., & Siegbahn, A. G. (2009) · American Heart Journal · doi:10.1016/j.ahj.2008.11.021 · Cited by 94
Klein, M. D., Williams, A. K., Lee, C. R., & Stouffer, G. A. (2019) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.118.311963 · Cited by 96
Schiele, F., Aktaa, S., Rossello, X., Ahrens, I., Claeys, M. J., Collet, J.-P., Fox, K. A. A., Gale, C. P., Huber, K., Iakobishvili, Z., et al. (2021) · European Heart Journal Acute Cardiovascular Care · doi:10.1093/ehjacc/zuaa037 · Cited by 93
Kosuge, M., Ebina, T., Hibi, K., Morita, S., Endo, M., Maejima, N., Iwahashi, N., Okada, K., Ishikawa, T., Umemura, S., et al. (2010) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2010.10.005 · Cited by 99
Koskinas, K. C., Räber, L., Zanchin, T., Wenaweser, P., Stortecky, S., Moschovitis, A., Khattab, A. A., Pilgrim, T., Blöchlinger, S., Moro, C., et al. (2015) · Circulation Cardiovascular Interventions · doi:10.1161/circinterventions.114.002053 · Cited by 93
Platelet ADP-receptor antagonists for cardiovascular disease: past, present and future
Raju, N. C., Eikelboom, J. W., & Hirsh, J. (2008) · Nature Clinical Practice Cardiovascular Medicine · doi:10.1038/ncpcardio1372 · Cited by 99
Abu‐Assi, E., López-López, A., Salvado, V. G., Diéguez, A. R., Peña, C., Bouzas‐Cruz, N., Raposeiras‐Roubín, S., Abumuaileq, R. R.-Y., García‐Acuña, J. M., & González‐Juanatey, J. R. (2015) · Revista Española de Cardiología · doi:10.1016/j.recesp.2015.06.016 · Cited by 94
Angiolillo, D. J., Curzen, N. P., Gurbel, P. A., Vaitkus, P. T., Lipkin, F., Li, W., Jakubowski, J. A., Zettler, M. E., Effron, M. B., & Trenk, D. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.11.032 · Cited by 94
Medical Management After Coronary Stent Implantation: A Review
Brilakis, E. S., PATEL, V. G., & Banerjee, S. (2013) · JAMA · doi:10.1001/jama.2013.7086 · Cited by 93
Iqbal, J., Sumaya, W., Tatman, V., Parviz, Y., Morton, A. C., Grech, E. D., Campbell, S., Storey, R. F., & Gunn, J. P. (2013) · EuroIntervention · doi:10.4244/eijv9i1a10 · Cited by 92
Characterization of the Average Daily Ischemic and Bleeding Risk After Primary PCI for STEMI
Giustino, G., Mehran, R., Dangas, G., Kirtane, A. J., Redfors, B., Généreux, P., Brener, S. J., Prats, J., Pocock, S., Deliargyris, E., et al. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.08.018 · Cited by 100
“In contrast, although the use of prasugrel rather than clopidogrel in patients with acute coronary syndromes (ACSs) was highly effective in reducing adverse ischemic events early after PCI, the excessive bleeding complications with this irreversible agent (including an increase in fatal and life-threatening bleeding)…”
Darmon, A., Bhatt, D. L., Elbez, Y., Aboyans, V., Anand, S. S., Bosch, J., Branch, K. R., Connolly, S. J., Dyal, L., Eikelboom, J. W., et al. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx658 · Cited by 98
Cangrelor: Clinical Data, Contemporary Use, and Future Perspectives
Luca, L. D., Steg, P. G., Bhatt, D. L., Capodanno, D., & Angiolillo, D. J. (2021) · Journal of the American Heart Association · doi:10.1161/jaha.121.022125 · Cited by 94
Advances in Antiplatelet Therapy: Agents in Clinical Development
Angiolillo, D. J., Bhatt, D. L., Gurbel, P. A., & Jennings, L. K. (2009) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2008.11.023 · Cited by 92
Welsh, R. C., Rao, S. V., Zeymer, U., Thompson, V. P., Huber, K., Kochman, J., McClure, M. W., Gretler, D. D., Bhatt, D. L., Gibson, C. M., et al. (2012) · Circulation Cardiovascular Interventions · doi:10.1161/circinterventions.111.964197 · Cited by 91
Self-citationSherwood, M. W., Wiviott, S. D., Peng, S. A., Roe, M. T., deLemos, J. A., Peterson, E. D., & Wang, T. Y. (2014) · Journal of the American Heart Association · doi:10.1161/jaha.114.000849 · Cited by 92
“In a randomized controlled trial of prasugrel versus clopidogrel in patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI), prasugrel significantly reduced major adverse cardiovascular event rates compared with clopidogrel, but had higher rates of major bleeding.(8) Secondary a…”
BackgroundInfluentialSelf-citationVarenhorst, C., Alström, U., Scirica, B. M., Hogue, C. W. J., Åsenblad, N., Storey, R. F., Steg, P. G., Horrow, J. C., Mahaffey, K. W., Becker, R. C., et al. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.07.021 · Cited by 91
Nonadherence to treatment protocol in published randomised controlled trials: a review
Dodd, S., White, I. R., & Williamson, P. (2012) · Trials · doi:10.1186/1745-6215-13-84 · Cited by 90
Metadata
- Authors
- Wiviott, S. D., Braunwald, E., McCabe, C. H., Montalescot, G., Ruzyllo, W., Gottlieb, S., Neumann, F.-J., Ardissino, D., De Servi, S., Murphy, S. A., Riesmeyer, J., Weerakkody, G., Gibson, C. M., & Antman, E. M.
- Affiliations
- Brigham and Women's Hospital (US)
- Inserm (FR)
- Bikur Cholim Hospital (IL)
- Universitäts-Herzzentrum Freiburg-Bad Krozingen (DE)
- Ospedale di Parma (IT)
- Eli Lilly (United States) (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2007-11-15
- Volume
- 357
- Issue
- 20
- Pages
- 2001-2015
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2169387542
- Cited by
- 6,790
- References
- 40
- Citations by year
- 2026: 162 · 2025: 202 · 2024: 187 · 2023: 265 · 2022: 309 · 2021: 326 · 2020: 339 · 2019: 361 · 2018: 389 · 2017: 418 · 2016: 419 · 2015: 465 · 2014: 448 · 2013: 502 · 2012: 507
- FWCI
- 238.04
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Coronary Interventions and Diagnostics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
- Keywords
- prasugrel, clopidogrel, acute coronary syndrome, percutaneous coronary intervention, dual antiplatelet therapy, thienopyridines, major bleeding, stent thrombosis, myocardial infarction, target vessel revascularization, cardiovascular mortality, bleeding risk stratification, bleeding risk score
- MeSH terms
- Prasugrel Hydrochloride, Clopidogrel, Aged, Aspirin, Double-Blind Method, Drug Therapy, Combination, Female, Hemorrhage, Humans, Male, Middle Aged, Myocardial Infarction, Piperazines, Platelet Aggregation Inhibitors, Prodrugs, Thiophenes, Thrombosis, Ticlopidine, Angioplasty, Balloon, Coronary, Stroke, Kaplan-Meier Estimate, Acute Coronary Syndrome, Purinergic P2 Receptor Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.